Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 44

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 44
---
 submitting a written demand for appraisal in the form described in this Proxy Statement/Prospectus prior to the vote to approve the Merger Agreement Proposal,
and must otherwise follow the procedures prescribed by Section 262 of the DGCL. A person having a beneficial interest in shares of Enfusion Common Stock or Enfusion Class B Common Stock held of record in the name of another person, such as
a nominee or intermediary, must follow additional steps summarized in this Proxy Statement/Prospectus and in a timely manner to perfect appraisal rights.

The text of Section 262 of the DGCL is attached as Annex E to this Proxy Statement/Prospectus. You are encouraged to read these
provisions carefully and in their entirety. Due to the complexity of the procedures for exercising appraisal rights, Enfusion Stockholders who are considering exercising such rights are encouraged to seek the advice of legal counsel and their
financial advisors. Failure to strictly comply with these provisions may result in the loss of appraisal rights.

No Solicitation of Other Offers by Enfusion(see page 132)

Under the terms of the Merger Agreement, Enfusion has agreed not to solicit, encourage or
facilitate any competing acquisition proposals for Enfusion, enter into discussions or negotiations with any third parties regarding any competing acquisition proposals for Enfusion or enter into any agreements with a third party regarding any
competing acquisition proposals for Enfusion.

Notwithstanding the foregoing restrictions, if prior to Enfusion Stockholders adopting the
Merger Agreement at the Special Meeting Enfusion receives an unsolicited competing acquisition proposal that the Enfusion Board determines to be superior to the Transactions or reasonably be expected to lead to a proposal that is superior to the
Transactions, Enfusion is permitted, subject to certain conditions set forth in the Merger

24

Agreement, to engage in discussions and negotiations with the party that sent the competing acquisition proposal (and its representatives, advisors and financing sources) and to furnish non-publicinformation to that party (and its representatives, advisors and debt financing sources). Under the terms of the Merger Agreement and subject to certain conditions set forth therein (including the payment of a $52,350,000 termination fee), Enfusion may terminate the Merger Agreement prior to Enfusion Stockholders adopting the Merger Agreement at the Special Meeting to accept a competing acquisition proposal that the Enfusion Board has determined to be superior to the Transactions from a financial point of view. See “The Merger Agreement—No Solicitation of Other Offers by Enfusion” and “The Merger Agreement